Flexion Therapeutics Inc (FLXN) Insider Acquires $50,069.76 in Stock

Flexion Therapeutics Inc (NASDAQ:FLXN) insider Michael D. Clayman purchased 4,012 shares of the company’s stock in a transaction on Friday, May 10th. The shares were purchased at an average cost of $12.48 per share, with a total value of $50,069.76. Following the purchase, the insider now owns 74,868 shares of the company’s stock, valued at $934,352.64. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

FLXN stock traded up $0.57 during mid-day trading on Thursday, hitting $13.16. 1,389 shares of the stock were exchanged, compared to its average volume of 673,421. The company has a quick ratio of 6.06, a current ratio of 6.32 and a debt-to-equity ratio of 2.10. Flexion Therapeutics Inc has a 12 month low of $9.65 and a 12 month high of $29.10. The firm has a market cap of $464.27 million, a P/E ratio of -2.89 and a beta of 1.56.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.13) by $0.04. Flexion Therapeutics had a negative return on equity of 131.94% and a negative net margin of 549.07%. The firm had revenue of $10.56 million during the quarter, compared to analyst estimates of $11.10 million. As a group, research analysts expect that Flexion Therapeutics Inc will post -4.07 EPS for the current fiscal year.

Several brokerages have issued reports on FLXN. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 6th. BidaskClub lowered Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, March 16th. Laidlaw set a $18.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 11th. ValuEngine lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Wednesday, April 10th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $23.71.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FLXN. Carroll Financial Associates Inc. increased its holdings in shares of Flexion Therapeutics by 100.0% in the fourth quarter. Carroll Financial Associates Inc. now owns 2,000 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 1,000 shares during the period. Next Capital Management LLC purchased a new position in shares of Flexion Therapeutics in the fourth quarter worth about $84,000. BNP Paribas Arbitrage SA increased its holdings in shares of Flexion Therapeutics by 53,692.3% in the first quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 6,980 shares during the period. Advisor Group Inc. increased its holdings in shares of Flexion Therapeutics by 68.2% in the fourth quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 3,490 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its holdings in shares of Flexion Therapeutics by 341.0% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,455 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 8,084 shares during the period. Hedge funds and other institutional investors own 94.96% of the company’s stock.

WARNING: “Flexion Therapeutics Inc (FLXN) Insider Acquires $50,069.76 in Stock” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.chaffeybreeze.com/2019/05/16/flexion-therapeutics-inc-flxn-insider-acquires-50069-76-in-stock.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Article: What is the NASDAQ?

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.